Vaxcyte Reports Q3 GAAP EPS of -$1.99, Exceeding Analyst Expectations
Vaxcyte (PCVX) reported third-quarter GAAP earnings per share of -$1.99, which outperformed market estimates by $0.15. Despite the net loss, the company's earnings performance exceeded consensus expectations for the period. As of September 30, 2026, Vaxcyte held $2,264.4 million in cash, cash equivalents, and investments, a decrease from $2,442.6 million at the end of December 2025. The company also noted that it expects to receive approximately $1.1 billion in net proceeds from offerings conducted in October 2026.
Tickers: $PCVX